Bioclinic EMIQ, Quercetin, a dietary flavonol known to be one of the most potent plant-derived antioxidants, has multiple biological actions, with anti-inflammatory, anti-thrombotic and vasodilatory benefits in pre-clinical studies.
The limiting factor in quercetin’s clinical efficacy appears to be its poor bioavailability. Enzymatically modified isoquercitrin (EMIQ) is a mixture of quercetin mono-glucoside and its alpha-oligo-glucosides that has been shown to have significantly greater bioavailability than other available forms. In animals, EMIQ was shown to produce a 40 fold increase in Cmax (peak plasma concentration) and an 18-fold increase in the area under the curve compared to quercetin. In humans, EMIQ supplementation increased plasma concentrations to a significantly greater degree than other forms, including aglycone and isoquercitrin, with randomized placebo-controlled trials documenting the improvement in allergic symptoms. EMIQ has also shown significantly enhanced biological activity especially in animal models of allergy and neoplasia.
NPN#:80049716